Wilmington , NC. April 7 2014. Accugenomics and The Uuniversity of Toledo have finalized a exclusive license agreement that provides Accugenomics worldwide rights to commercialize STARSEQ™ Technology. STARSEQ technology will fulfill a next generation sequencing need to run at very low cost, quality controlled and reproducible multigene transcript abundance analysis in large numbers of samples across laboratories, methods and platforms. STARSEQ generates data suitable for regulatory review because each gene of every sample is measured relative to a known number of synthetic internal standard molecules. The technology will be marketed for R&D researchers demanding better quality controls, throughput, accuracy and reproducibility over time. The technology’s greatest benefit is at clinical applications of RNAseq on targeted therapies.